Recent increase in the demand is owed to the rising incidences of cancer & HIV cases. World Health Organization growth estimations show a huge potential for the market with the arrival of new therapeutic preventive, and adult vaccines.
Asia-Pacific Preventive Vaccine Market is valued at $6.15 Billion in 2018 and is estimated to reach $11.79 billion by the end of 2023 with a CAGR of 13.89 %.
The vaccine Market is quite different from any other product market, having distinct features with increased complexity of assessing, understanding prices and procurement. Although it is a small market compared to the pharmaceutical market, we cannot dismiss the fact that it is growing at a fast rate. There are currently around 120 new vaccines in the pipeline of various multinational companies across the world and are set to hit the market in the coming years. While the vaccine market is rather concentrated on both supply and demand sides, it is mostly dependent on public purchasers and donor policies.
Invested from governments for vaccine development, increase in funding by the major market players, rising occurrence of disease, technological advancements decreasing the new vaccine development time drastically, initiatives by NGO’s are some of the factors that are propelling the growth of vaccines market. However, massive capital requirement and stringent regulatory policies, high costs associated with treatment are few factors crippling the growth of the market.
The Asia-Pacific Preventive Vaccines Market is segmented on the basis of vaccine type as vaccine as Live, attenuated vaccines, inactivated vaccines, Toxoid vaccines, Subunit vaccines, Conjugate vaccines, DNA vaccines and Recombinant vector vaccines. In addition, based on age groups the market is segmented as Paediatric Vaccine (Pneumococcal, MMR, Varicella, Hepatitis, Poliovirus, HIB and others) and Adult vaccines (Influenza, Cervical Cancer, Hepatitis, Zoster and others). And also, based on geography, the Asia-Pacific Market is analysed under various regions namely, India, China, Japan and South Korea.
Multinational vaccine companies historically have conducted much of the innovation, research, and development in the field of vaccine production. They have used significant revenues and deeper expertise to fund their works. Some of the key players influencing the Asia-Pacific preventive vaccine market are GlaxoSmithKline, plc., Merck and Company, Bavarian Nordic, CSL Limited, Emergent BioSolutions Inc., Novartis AG, Johnson and Johnson, MedImmune, LLC, Pfizer, Inc., and Sanofi Pasteur.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2.1 Introduction
2.2 Analysis Design
2.3 Research Phases
2.3.1 Secondary Research
2.3.2 Primary Research
2.3.3 Econometric Modelling
2.3.4 Expert Validation
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5.1 By Vaccine Type
5.1.1 Live, Attenuated Vaccines
5.1.2 Inactivted Vaccines
5.1.3 Toxoid Vaccines
5.1.4 Subunit vaccines
5.1.5 Conjugate vaccines
5.1.6 DNA vaccines
5.1.7 Recombinant vector vaccines
5.2 By End User
5.2.1 Paediatric Vaccine
5.2.1.1 Pneumococcal
5.2.1.2 MMR
5.2.1.3 Varicella
5.2.1.4 Hepatitis
5.2.1.5 Poliovirus
5.2.1.6 HIB
5.2.1.7 Others
5.2.2 Adult Vaccines
5.2.2.1 Influenza
5.2.2.2 Cervical Cancer
5.2.2.3 Hepatitis
5.2.2.4 Zoster
5.2.2.5 Others
6.1 Introduction
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.1 GlaxoSmithKline, plc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Merck and Company
8.3 Bavarian Nordic
8.4 CSL Limited
8.5 Emergent BioSolutions Inc.
8.6 Novartis AG
8.7 Johnson and Johnson
8.8 MedImmune, LLC
8.9 Pfizer, Inc.
8.10 Sanofi Pasteur
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
